Immune checkpoint inhibitors (ICIs) are a mainstay of immunotherapy for many cancer types — including breast, colon, liver, lung, skin, stomach, and rectal — but cancer care often brings challenging skin side effects that patients (and even physicians) may not expect. Feature article in American Academy of Dermatology’s DermWorld. March 01, 2024